Comparing Cartesian Therapeutics (NASDAQ:RNAC) & Rapport Therapeutics (NASDAQ:RAPP)

Cartesian Therapeutics (NASDAQ:RNAC) and Rapport Therapeutics (NASDAQ:RAPP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, profitability, institutional ownership, risk, dividends and earnings.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Cartesian Therapeutics and Rapport Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	0	1	7	0	2.88
Rapport Therapeutics	0	0	3	0	3.00

Cartesian Therapeutics currently has a consensus price target of $42.33, suggesting a potential upside of 103.92%. Rapport Therapeutics has a consensus price target of $35.00, suggesting a potential upside of 31.14%. Given Cartesian Therapeutics’ higher probable upside, equities analysts plainly believe Cartesian Therapeutics is more favorable than Rapport Therapeutics.

Profitability

This table compares Cartesian Therapeutics and Rapport Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-424.47%	N/A	-5.85%
Rapport Therapeutics	N/A	N/A	N/A

Valuation and Earnings

This table compares Cartesian Therapeutics and Rapport Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$26.00 million	17.08	-$219.71 million	N/A	N/A
Rapport Therapeutics	N/A	N/A	-$34.79 million	N/A	N/A

Rapport Therapeutics has lower revenue, but higher earnings than Cartesian Therapeutics.

Insider & Institutional Ownership

87.0% of Cartesian Therapeutics shares are held by institutional investors. 57.9% of Cartesian Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Cartesian Therapeutics beats Rapport Therapeutics on 5 of the 9 factors compared between the two stocks.

About Cartesian Therapeutics

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

About Rapport Therapeutics

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.